Yifang Wu

Mr. Wu, aged 56, has more than 35 years of experience in the biopharmaceutical industry. He currently serves as an executive operating partner of CBC Group, a substantial shareholder of Everest Medicines. Prior to joining Everest, he served as Executive President of Fosun International and was Chairman & CEO of Fosun Pharma for nearly a decade.

During his tenure at Fosun Pharma, he spearheaded the company's transformation into a global leader, notably securing BioNTech's mRNA technology for Greater China during the early stages of the pandemic. Wu also co-founded Wanbang Biopharmaceuticals and led the company as its Chairman & CEO, establishing a strong foundation in biopharmaceutical innovation.

Wu obtained an Executive Master of Business Administration (EMBA) from Saint Joseph's University in the United States in 2005. He has also been a non-executive director of Sisram Medical Ltd.

Career History

• Chairman & CEO, Fosun Pharma (approximately 2016–2025)
• Executive President, Fosun International
• Chairman & CEO, Wanbang Biopharmaceuticals (co-founder)
• Non-Executive Director, Sisram Medical Ltd

What Yifang Wu could bring to Everest Medicines: Wu's appointment signals Everest's strategic pivot toward mRNA therapeutics and oncology-focused innovation. His proven track record transforming Fosun Pharma into a global biopharmaceutical leader—particularly through securing transformative partnerships like BioNTech's mRNA technology for Greater China—positions him to accelerate Everest's dual-engine strategy. His deep expertise in clinical development, commercialization infrastructure, and international healthcare partnerships could be instrumental in scaling Everest's personalized cancer vaccine program and expanding its presence across Asia-Pacific markets.